Key topics in HCC discussed at ASCO GI & EASL liver cancer summit 2022

Episode 1 February 28, 2022 00:13:11
Key topics in HCC discussed at ASCO GI & EASL liver cancer summit 2022
COR2ED Medical Education
Key topics in HCC discussed at ASCO GI & EASL liver cancer summit 2022

Feb 28 2022 | 00:13:11

/

Show Notes

Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab in the frontline setting with patients with unresectable hepatocellular carcinoma. There were other important studies at the meeting and Prof Harding highlights the RENOBATE study and the GOING study that evaluated nivolumab in combination with regorafenib and early addition of nivolumab to regorafenib regimen, respectively.

Other Episodes

Episode 1

March 14, 2023 00:24:54
Episode Cover

Advanced HCC and not eligible for IO – what are the treatment options?

COR2ED Medical Education: Prof. Dr James Harding, Medical Oncologist at Memorial Sloan Kettering Cancer Center and Prof. Dr Sammy Saab, Gastroenterologist and Transplant Hepatologist...

Listen

Episode

November 27, 2023 00:19:16
Episode Cover

Perioperative Thromboprophylaxis Revisited

Thrombotic risk is a constant threat in perioperative patients, but it has decreased with the evolution of surgical technology.  Do you know how to...

Listen

Episode 3

February 10, 2022 00:26:43
Episode Cover

PARP inhibitors in prostate cancer: Management of adverse events and the importance of communication with patients

COR2ED Medical Education: Dr Jason Alcorn, nurse consultant for Uro-Oncology & Andrology at the Mid Yorkshire Hospitals NHS Trust, United Kingdom and Dr Alicia...

Listen